BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 20492521)

  • 1. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.
    Salerno F; Guevara M; Bernardi M; Moreau R; Wong F; Angeli P; Garcia-Tsao G; Lee SS
    Liver Int; 2010 Aug; 30(7):937-47. PubMed ID: 20492521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of ascites in cirrhosis.
    Sandhu BS; Sanyal AJ
    Clin Liver Dis; 2005 Nov; 9(4):715-32, viii. PubMed ID: 16207572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis.
    Gentilini P; Laffi G; La Villa G; Raggi VC
    Ann Ital Med Int; 1999; 14(4):264-84. PubMed ID: 10638019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refractory ascites: definition, pathogenesis and treatment.
    Laffi G; La Villa G; Pinzani M; Foschi M; Carloni V; Casini Raggi V; Gentilini P
    Ann Ital Med Int; 1993; 8(1):38-46. PubMed ID: 8485009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.
    Senzolo M; Cholongitas E; Tibballs J; Burroughs A; Patch D
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1143-50. PubMed ID: 17033432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites.
    Wong W; Liu P; Blendis L; Wong F
    Am J Med; 1999 Mar; 106(3):315-22. PubMed ID: 10190381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ascites: diagnosis and management.
    Hou W; Sanyal AJ
    Med Clin North Am; 2009 Jul; 93(4):801-17, vii. PubMed ID: 19577115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
    Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
    Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of ascites and hepatorenal syndrome.
    Piano S; Tonon M; Angeli P
    Hepatol Int; 2018 Feb; 12(Suppl 1):122-134. PubMed ID: 28836115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascites and Hepatorenal Syndrome.
    Adebayo D; Neong SF; Wong F
    Clin Liver Dis; 2019 Nov; 23(4):659-682. PubMed ID: 31563217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.
    Rössle M; Ochs A; Gülberg V; Siegerstetter V; Holl J; Deibert P; Olschewski M; Reiser M; Gerbes AL
    N Engl J Med; 2000 Jun; 342(23):1701-7. PubMed ID: 10841872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatorenal syndrome.
    Bataller R; Arroyo V; Ginès P; Sort P
    Forum (Genova); 1998; 8(1):62-81. PubMed ID: 9565447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of surgery in the treatment of refractory ascites in cirrhotic patients].
    Borie DC; Vaillant JC; Breton S; Hannoun L
    Ann Chir; 1999; 53(10):966-72. PubMed ID: 10670142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology, diagnosis and treatment of ascites in cirrhosis.
    Arroyo V
    Ann Hepatol; 2002; 1(2):72-9. PubMed ID: 15115971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatorenal syndrome.
    Biswas KD; Jain AK
    Trop Gastroenterol; 2002; 23(3):113-6. PubMed ID: 12693150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluid retention in cirrhosis: pathophysiology and management.
    Kashani A; Landaverde C; Medici V; Rossaro L
    QJM; 2008 Feb; 101(2):71-85. PubMed ID: 18184668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
    Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G
    Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.
    Ochs A; Rössle M; Haag K; Hauenstein KH; Deibert P; Siegerstetter V; Huonker M; Langer M; Blum HE
    N Engl J Med; 1995 May; 332(18):1192-7. PubMed ID: 7700312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: Management of ascites and associated complications in patients with cirrhosis.
    Kuiper JJ; de Man RA; van Buuren HR
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():183-93. PubMed ID: 18081661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.